10-K · March 12, 2026
IN8bio, Inc. continues to struggle financially, reporting a net loss of $19.4 million for 2025, without generating any revenue. Management highlighted advancements in clinical trials but maintained a cautious approach…
Earnings analysis · 10-Q
INAB earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
IN8bio, Inc. reported a net loss of $5.1 million for Q1 2026 compared to a net loss of $5.6 million in Q1 2025, demonstrating improved performance. There were no revenues reported, and management highlighted ongoing…
Read full summary
IN8bio, Inc. reported a net loss of $5.1 million for Q1 2026 compared to a net loss of $5.6 million in Q1 2025, demonstrating improved performance. There were no revenues reported, and management highlighted ongoing financial challenges but indicated progress in clinical developments related to its gamma-delta T cell therapies.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.26
What stood out
-
Reduced Net Loss
Net loss decreased to $5.1 million in Q1 2026 from $5.6 million in Q1 2025.
-
Improved EPS
Q1 2026 diluted EPS improved to -$0.26 compared to -$2.16 in the prior year.
-
Increased Cash Reserves
Cash increased to $21.9 million as of March 31, 2026.
-
Decrease in Operating Expenses
Total operating expenses fell to $5.3 million in Q1 2026 from $5.7 million in Q1 2025.
-
Growth in Interest Income
Interest income rose to $200,000 in Q1 2026 from $100,000 in Q1 2025.
-
Clinical Trial Advances
Management reported ongoing progress in Phase 1 trials and plans for an expansion cohort in the INB-100 trial.
What to watch
-
Going Concern Doubts
There is substantial doubt about the company's ability to continue as a going concern, with cash expected to fund operations only through April 2027.
-
Dependence on Clinical Trial Outcomes
Future revenue is highly dependent on the success of ongoing clinical trials and obtaining regulatory approvals.
-
Limited Revenue Generation
The company has not generated any revenue since inception, raising concerns about long-term viability.
Management's outlook
Management expects to achieve meaningful clinical milestones.
Earlier filings 4
10-Q · November 6, 2025
INAB's Q3 2025 results show a continued absence of revenue, with net losses improving to $3.85 million from $7.09 million year-over-year. Operating expenses have decreased significantly, attributed to reduced research…
10-Q · August 7, 2025
IN8bio, Inc. reported a net loss of $5.1 million for Q2 2025, a decrease from $8.7 million in Q2 2024, with no revenue recorded. The company continues to navigate challenges related to clinical trials, regulatory…
10-Q · May 7, 2025
IN8bio reported its Q1 2025 results with no revenue, consistent with prior quarters, and an EPS of -$2.10, signifying an ongoing financial struggle. Operating expenses decreased from $8.6 million in Q1 2024 to $5.7…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.